PARD3B and intrahepatic cholangiocarcinoma: The increased levels of TMED2 and PARD3B led to activation of the AKT/GSK/β-catenin and MEK/ERK/Slug signaling pathways, promoting the expression of EMT markers vimentin and N-cadherin while inhibiting E-cadherin expression, thereby promoting the metastasis and EMT of ICC [68].